ARTICLE | Finance
Buying back in
Investors banking second time is charm for Chelsea's Northera
January 20, 2014 8:00 AM UTC
Investors in Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) are hoping the near unanimity of last week's positive FDA panel vote means it won't be déjà vu when FDA makes its decision on Northera droxidopa.
The stock jumped last week when the Cardiovascular and Renal Drugs Advisory Committee voted 16-1 to support approval of Northera to treat symptomatic neurogenic orthostatic hypotension (NOH), a sudden fall in blood pressure when standing...